Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Companies / Japan

MNC Products Key To Japanese Firms' Success?

May 2006 | Company Finance Alert

Results for the 2005-06 financial year released by Japanese companies illustrate that products developed by foreign firms are playing a key role in the fortunes of the indigenous industry. At a time of tough conditions in the home market, large Japanese companies with scale in overseas markets and a strong in-house portfolio are the best

Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.

[
: *
[
: *

Forgotten your password?

If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.

Related Insight Articles
Observers Optimistic On Takeda Profits

Companies / Japan A report published in leading Japanese business newspaper Nihon Keizai claims that leading indigenous drugmaker Takeda's recurring profit could exceed JPY500bn (US$4.2bn) this financial year - more...
October 2006
Industry Slams Japan's Regulatory Reforms

Companies / Japan Stakeholders in Japan's drug industry have criticised the government's handling of its five-year industry plan. The strategy was first outlined in 2002, and a draft version of the new five-year plan...
June 2006
Takeda Boosts R&D Spend, Market Share

Companies / Japan Leading Japanese drugmaker Takeda is to invest US$1.8bn in research and development in fiscal year 2006/07, according to local reports. Other leading local firms are also expected to boost R&D budgets...
May 2006
Japan's Tough Market To Separate Winners, Losers

Companies / Japan Heavy spending on product in-licensing and imminent patent expiries are set to bring mixed fortunes for Japan's leading drugmakers, according to local observers. In the coming years, the success of operations...
May 2006
Chugai Files Avastin, Reports Profit Drop

Companies / Japan Chugai, the Japanese affiliate of Swiss pharmaceutical major Roche, has filed a submission for colorectal cancer drug Avastin (bevacizumab) with the health ministry. A new ministry committee is expected...
April 2006


All material on this site is protected by international copyright laws and use of this site is subject to our Terms & Conditions.
© 2009 Business Monitor International Ltd
Site powered by WORKSsitebuilder CMS